Theravance Biopharma, Inc. (TBPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q3 '16: 46.8M Q4 '16: 48.6M Q1 '17: 33.3M Q2 '17: 31.4M Q3 '17: 16.6M Q4 '17: 15.4M Q1 '18: 20.6M Q2 '18: 40.6M Q3 '18: 49.1M Q4 '18: 60.4M Q1 '19: 57.4M Q2 '19: 60.1M Q3 '19: 59.7M Q4 '19: 73.4M Q1 '20: 87.9M Q2 '20: 76.8M Q3 '20: 82.6M Q4 '20: 71.9M Q1 '21: 66.3M Q2 '21: 64.2M Q3 '21: 59.1M Q4 '21: 55.3M Q1 '22: 54.2M Q2 '22: 52.4M Q3 '22: 51.6M Q4 '22: 51.3M Q1 '23: 48.6M Q2 '23: 51.3M Q3 '23: 54.5M Q4 '23: 57.4M Q1 '24: 61.5M Q2 '24: 62M Q3 '24: 63.2M Q4 '24: 64.4M Q1 '25: 65.3M Q2 '25: 77.2M Q3 '25: 80.3M Q4 '25: 107.5M Q1 '26: 109.8M Q2 '26: 104.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -178.4M Q4 '16: -180.5M Q1 '17: -197.7M Q2 '17: -215.3M Q3 '17: -238.8M Q4 '17: -260.1M Q1 '18: -266.3M Q2 '18: -249.9M Q3 '18: -255.3M Q4 '18: -238.8M Q1 '19: -247.4M Q2 '19: -241.2M Q3 '19: -244M Q4 '19: -251.9M Q1 '20: -250.7M Q2 '20: -280.4M Q3 '20: -291.8M Q4 '20: -297.8M Q1 '21: -309.2M Q2 '21: -301.1M Q3 '21: -278.1M Q4 '21: -257.8M Q1 '22: -211.1M Q2 '22: -170.1M Q3 '22: -130.7M Q4 '22: -92M Q1 '23: -79.6M Q2 '23: -72.7M Q3 '23: -67.2M Q4 '23: -56M Q1 '24: -42.3M Q2 '24: -41.9M Q3 '24: -44M Q4 '24: -46.9M Q1 '25: -50.2M Q2 '25: -37.2M Q3 '25: -32.8M Q4 '25: -3.6M Q1 '26: 1.3M Q2 '26: -4.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-300M 0 300M 600M 900M Q3 '16: -168.2M Q4 '16: -190.7M Q1 '17: -213.8M Q2 '17: -232.9M Q3 '17: -265.8M Q4 '17: -285.4M Q1 '18: -285.2M Q2 '18: -259.7M Q3 '18: -252.3M Q4 '18: -215.5M Q1 '19: -223M Q2 '19: -222M Q3 '19: -221M Q4 '19: -236.5M Q1 '20: -246.9M Q2 '20: -270M Q3 '20: -285.2M Q4 '20: -278M Q1 '21: -274.6M Q2 '21: -264.2M Q3 '21: -225.8M Q4 '21: -199.4M Q1 '22: -145.7M Q2 '22: -101.5M Q3 '22: 850.5M Q4 '22: 872.1M Q1 '23: 876M Q2 '23: 868.5M Q3 '23: -57M Q4 '23: -55.2M Q1 '24: -44.8M Q2 '24: -45.7M Q3 '24: -49.4M Q4 '24: -56.4M Q1 '25: -58.3M Q2 '25: 13M Q3 '25: 29.3M Q4 '25: 105.9M Q1 '26: 114.5M Q2 '26: 53.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q3 '16: -104.6M Q4 '16: -99M Q1 '17: -122.7M Q2 '17: -135.1M Q3 '17: -185M Q4 '17: -201.1M Q1 '18: -101.2M Q2 '18: -118.2M Q3 '18: -104.9M Q4 '18: -112.9M Q1 '19: -243.9M Q2 '19: -230.4M Q3 '19: -226M Q4 '19: -238.2M Q1 '20: -212.1M Q2 '20: -217.4M Q3 '20: -249.8M Q4 '20: -250.4M Q1 '21: -265.2M Q2 '21: -261.9M Q3 '21: -230.3M Q4 '21: -207.9M Q1 '22: -164.1M Q2 '22: -128.7M Q3 '22: -105.4M Q4 '22: -187M Q1 '23: -172.1M Q2 '23: -169.8M Q3 '23: -150.2M Q4 '23: -27M Q1 '24: -16.8M Q2 '24: -8.8M Q3 '24: -11.5M Q4 '24: -11.5M Q1 '25: 32.5M Q2 '25: 245M Q3 '25: 243.7M Q4 '25: 238.5M Q1 '26: 268.8M Q2 '26: 53.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q1 '15: -189M Q2 '15: -184.6M Q3 '15: -180.5M Q4 '15: -171.5M Q1 '16: -141.3M Q2 '16: -126.8M Q3 '16: -107M Q4 '16: -101.1M Q1 '17: -124.7M Q2 '17: -137.2M Q3 '17: -187.5M Q4 '17: -203.5M Q1 '18: -105.8M Q2 '18: -123.2M Q3 '18: -110.9M Q4 '18: -120.1M Q1 '19: -249.6M Q2 '19: -235.5M Q3 '19: -229.4M Q4 '19: -241.4M Q1 '20: -215M Q2 '20: -222.1M Q3 '20: -256.5M Q4 '20: -257M Q1 '21: -272.6M Q2 '21: -267.2M Q3 '21: -234.6M Q4 '21: -211.3M Q1 '22: -166M Q2 '22: -130.5M Q3 '22: -106.1M Q4 '22: -187.6M Q1 '23: -173.4M Q2 '23: -171.8M Q3 '23: -152.3M Q4 '23: -29.5M Q1 '24: -18.4M Q2 '24: -9.6M Q3 '24: -12.3M Q4 '24: -11.9M Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '18: 53.8M Q3 '18: 54.2M Q1 '19: 54.9M Q2 '19: 55.5M Q3 '19: 55.9M Q1 '20: 59.5M Q2 '20: 62.9M Q3 '20: 63.3M Q1 '21: 64.5M Q2 '21: 65.7M Q3 '21: 73.6M Q1 '22: 75.2M Q2 '22: 76.3M Q3 '22: 75.5M Q1 '23: 62.9M Q2 '23: 56.7M Q3 '23: 52.4M Q1 '24: 48.3M Q2 '24: 48.7M Q3 '24: 49M Q1 '25: 49.7M Q2 '25: 50.7M Q3 '25: 51.9M Q1 '26: 51.3M Q2 '26: 51.7M Q2 '18 Q3 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-8.00 -4.00 0.00 4.00 8.00 12.00 Q3 '16: -4.12 Q4 '16: -4.25 Q1 '17: -4.42 Q2 '17: -4.63 Q3 '17: -5.17 Q4 '17: -5.45 Q1 '18: -5.40 Q2 '18: -4.89 Q3 '18: -4.72 Q4 '18: -4.00 Q1 '19: -4.10 Q2 '19: -4.06 Q3 '19: -4.01 Q4 '19: -4.26 Q1 '20: -4.34 Q2 '20: -4.62 Q3 '20: -4.73 Q4 '20: -4.48 Q1 '21: -4.32 Q2 '21: -4.12 Q3 '21: -3.44 Q4 '21: -2.95 Q1 '22: -2.05 Q2 '22: -1.36 Q3 '22: 11.26 Q4 '22: 11.54 Q1 '23: 11.53 Q2 '23: 11.36 Q3 '23: -0.95 Q4 '23: -0.97 Q1 '24: -0.86 Q2 '24: -0.92 Q3 '24: -1.01 Q4 '24: -1.15 Q1 '25: -1.18 Q2 '25: 0.24 Q3 '25: 0.57 Q4 '25: 2.03 Q1 '26: 2.20 Q2 '26: 1.01 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.